{"pmid":32358956,"pmcid":"PMC7197530","title":"Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19.","text":["Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19.","BACKGROUND: A novel coronavirus, SARS-CoV-2, has recently emerged and caused the rapid spread of COVID-19 worldwide. METHODS: We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between February 1 and February 29, 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen. RESULTS: 112 patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhoea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both IgM and IgG, 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post disease onset, and lasted for one month and gradually decreased, while IgG antibody was produced 10 days after infection, and lasted for a longer time. However, no significant difference in level of IgM and IgG antibody between positive and negative patients of nucleic acid test after treatment was found. CONCLUSIONS: Our results indicate that serological tests could be powerful approach for the early diagnosis of COVID-19.","J Infect Dis","Zhang, Guoxin","Nie, Shuke","Zhang, Zhaohui","Zhang, Zhentao","32358956"],"abstract":["BACKGROUND: A novel coronavirus, SARS-CoV-2, has recently emerged and caused the rapid spread of COVID-19 worldwide. METHODS: We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between February 1 and February 29, 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen. RESULTS: 112 patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhoea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both IgM and IgG, 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post disease onset, and lasted for one month and gradually decreased, while IgG antibody was produced 10 days after infection, and lasted for a longer time. However, no significant difference in level of IgM and IgG antibody between positive and negative patients of nucleic acid test after treatment was found. CONCLUSIONS: Our results indicate that serological tests could be powerful approach for the early diagnosis of COVID-19."],"journal":"J Infect Dis","authors":["Zhang, Guoxin","Nie, Shuke","Zhang, Zhaohui","Zhang, Zhentao"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358956","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/infdis/jiaa229","keywords":["covid-19","sars-cov-2","antibody","humoral immunity","serological test"],"locations":["fatigue","myalgia"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495305908224,"score":9.490897,"similar":[{"pmid":32306047,"pmcid":"PMC7188146","title":"Antibody Detection and Dynamic Characteristics in Patients with COVID-19.","text":["Antibody Detection and Dynamic Characteristics in Patients with COVID-19.","BACKGROUND: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. METHODS: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. RESULTS: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. CONCLUSIONS: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.","Clin Infect Dis","Xiang, Fei","Wang, Xiaorong","He, Xinliang","Peng, Zhenghong","Yang, Bohan","Zhang, Jianchu","Zhou, Qiong","Ye, Hong","Ma, Yanling","Li, Hui","Wei, Xiaoshan","Cai, Pengcheng","Ma, Wan-Li","32306047"],"abstract":["BACKGROUND: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. METHODS: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. RESULTS: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. CONCLUSIONS: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays."],"journal":"Clin Infect Dis","authors":["Xiang, Fei","Wang, Xiaorong","He, Xinliang","Peng, Zhenghong","Yang, Bohan","Zhang, Jianchu","Zhou, Qiong","Ye, Hong","Ma, Yanling","Li, Hui","Wei, Xiaoshan","Cai, Pengcheng","Ma, Wan-Li"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32306047","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1093/cid/ciaa461","keywords":["covid-19","elisa","sars-cov-2","diagnosis","serological test"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493367091200,"score":434.74423},{"pmid":32198501,"pmcid":"PMC7184472","title":"Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).","text":["Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).","BACKGROUND: Emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. Current method of detection involves qPCR-based technique, which identifies the viral nucleic acids when present in sufficient quantity. False negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We here aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. METHODS: The host humoral response against SARS-CoV-2 including IgA, IgM and IgG response were examined by using an ELISA based assay on the recombinant viral nucleocapsid protein. Total 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but had typical manifestation). The diagnostic value of IgM was evaluated in this cohort. RESULTS: The median duration of IgM and IgA antibody detection were 5 days (IQR 3-6), while IgG was detected on 14 days (IQR 10-18) after symptom onset, with a positive rate of 85.4%, 92.7% and 77.9% respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR method after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combined IgM ELISA assay with PCR for each patient compare with a single qPCR test (51.9%). CONCLUSIONS: Humoral response to SARS-CoV-2 can aid to the diagnosis of COVID-19, including subclinical cases.","Clin Infect Dis","Guo, Li","Ren, Lili","Yang, Siyuan","Xiao, Meng","Chang, De","Yang, Fan","Dela Cruz, Charles S","Wang, Yingying","Wu, Chao","Xiao, Yan","Zhang, Lulu","Han, Lianlian","Dang, Shengyuan","Xu, Yan","Yang, Qiwen","Xu, Shengyong","Zhu, Huadong","Xu, Yingchun","Jin, Qi","Sharma, Lokesh","Wang, Linghang","Wang, Jianwei","32198501"],"abstract":["BACKGROUND: Emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. Current method of detection involves qPCR-based technique, which identifies the viral nucleic acids when present in sufficient quantity. False negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We here aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. METHODS: The host humoral response against SARS-CoV-2 including IgA, IgM and IgG response were examined by using an ELISA based assay on the recombinant viral nucleocapsid protein. Total 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but had typical manifestation). The diagnostic value of IgM was evaluated in this cohort. RESULTS: The median duration of IgM and IgA antibody detection were 5 days (IQR 3-6), while IgG was detected on 14 days (IQR 10-18) after symptom onset, with a positive rate of 85.4%, 92.7% and 77.9% respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR method after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combined IgM ELISA assay with PCR for each patient compare with a single qPCR test (51.9%). CONCLUSIONS: Humoral response to SARS-CoV-2 can aid to the diagnosis of COVID-19, including subclinical cases."],"journal":"Clin Infect Dis","authors":["Guo, Li","Ren, Lili","Yang, Siyuan","Xiao, Meng","Chang, De","Yang, Fan","Dela Cruz, Charles S","Wang, Yingying","Wu, Chao","Xiao, Yan","Zhang, Lulu","Han, Lianlian","Dang, Shengyuan","Xu, Yan","Yang, Qiwen","Xu, Shengyong","Zhu, Huadong","Xu, Yingchun","Jin, Qi","Sharma, Lokesh","Wang, Linghang","Wang, Jianwei"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198501","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1093/cid/ciaa310","keywords":["covid-19","elisa","antibody","diagnosis","novel coronavirus"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490091339776,"score":420.55722},{"pmid":32229605,"title":"Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2.","text":["Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2.","Background: At present, PCR-based nucleic acid detection cannot meet the demands for coronavirus infectious disease (COVID-19) diagnosis.Methods: 214 confirmed COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command of the People's Liberation Army between January 18 and February 26, 2020, were recruited. Two Enzyme-Linked Immunosorbent Assay (ELISA) kits based on recombinant SARS-CoV-2 nucleocapsid protein (rN) and spike protein (rS) were used for detecting IgM and IgG antibodies, and their diagnostic feasibility was evaluated.Results: Among the 214 patients, 146 (68.2%) and 150 (70.1%) were successfully diagnosed with the rN-based IgM and IgG ELISAs, respectively; 165 (77.1%) and 159 (74.3%) were successfully diagnosed with the rS-based IgM and IgG ELISAs, respectively. The positive rates of the rN-based and rS-based ELISAs for antibody (IgM and/or IgG) detection were 80.4% and 82.2%, respectively. The sensitivity of the rS-based ELISA for IgM detection was significantly higher than that of the rN-based ELISA. We observed an increase in the positive rate for IgM and IgG with an increasing number of days post-disease onset (d.p.o.), but the positive rate of IgM dropped after 35 d.p.o. The positive rate of rN-based and rS-based IgM and IgG ELISAs was less than 60% during the early stage of the illness 0-10 d.p.o., and that of IgM and IgG was obviously increased after 10 d.p.o.Conclusions: ELISA has a high sensitivity, especially for the detection of serum samples from patients after 10 d.p.o, it can be an important supplementary method for COVID-19 diagnosis.","J Clin Microbiol","Liu, Wanbing","Liu, Lei","Kou, Guomei","Zheng, Yaqiong","Ding, Yinjuan","Ni, Wenxu","Wang, Qiongshu","Tan, Li","Wu, Wanlei","Tang, Shi","Xiong, Zhou","Zheng, Shangen","32229605"],"abstract":["Background: At present, PCR-based nucleic acid detection cannot meet the demands for coronavirus infectious disease (COVID-19) diagnosis.Methods: 214 confirmed COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command of the People's Liberation Army between January 18 and February 26, 2020, were recruited. Two Enzyme-Linked Immunosorbent Assay (ELISA) kits based on recombinant SARS-CoV-2 nucleocapsid protein (rN) and spike protein (rS) were used for detecting IgM and IgG antibodies, and their diagnostic feasibility was evaluated.Results: Among the 214 patients, 146 (68.2%) and 150 (70.1%) were successfully diagnosed with the rN-based IgM and IgG ELISAs, respectively; 165 (77.1%) and 159 (74.3%) were successfully diagnosed with the rS-based IgM and IgG ELISAs, respectively. The positive rates of the rN-based and rS-based ELISAs for antibody (IgM and/or IgG) detection were 80.4% and 82.2%, respectively. The sensitivity of the rS-based ELISA for IgM detection was significantly higher than that of the rN-based ELISA. We observed an increase in the positive rate for IgM and IgG with an increasing number of days post-disease onset (d.p.o.), but the positive rate of IgM dropped after 35 d.p.o. The positive rate of rN-based and rS-based IgM and IgG ELISAs was less than 60% during the early stage of the illness 0-10 d.p.o., and that of IgM and IgG was obviously increased after 10 d.p.o.Conclusions: ELISA has a high sensitivity, especially for the detection of serum samples from patients after 10 d.p.o, it can be an important supplementary method for COVID-19 diagnosis."],"journal":"J Clin Microbiol","authors":["Liu, Wanbing","Liu, Lei","Kou, Guomei","Zheng, Yaqiong","Ding, Yinjuan","Ni, Wenxu","Wang, Qiongshu","Tan, Li","Wu, Wanlei","Tang, Shi","Xiong, Zhou","Zheng, Shangen"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32229605","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1128/JCM.00461-20","topics":["Diagnosis"],"weight":1,"_version_":1666138492232531972,"score":415.74176},{"pmid":32251798,"pmcid":"PMC7194885","title":"Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.","text":["Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.","OBJECTIVE: To investigate the diagnostic value of serological testing and dynamic variance of serum antibody in coronavirus disease 2019 (COVID-19). METHODS: This study retrospectively included 43 patients with a laboratory-confirmed infection and 33 patients with a suspected infection, in whom the disease was eventually excluded. The IgM/IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was measured by chemiluminescence immunoassay analysis. RESULTS: Compared to molecular detection, the sensitivities of serum IgM and IgG antibodies to diagnose COVID-19 were 48.1% and 88.9%, and the specificities were 100% and 90.9%, respectively.In the COVID-19 group, the IgM-positive rate increased slightly at first and then decreased over time; in contrast, the IgG-positive rate increased to 100% and was higher than IgM at all times. The IgM-positive rate and titer were not significantly different before and after conversion to virus-negative. The IgG-positive rate was up to 90% and not significantly different before and after conversion to virus-negative. However, the median IgG titer after conversion to virus-negative was double that before, and the difference was significant. CONCLUSIONS: Viral serological testing is an effective means of diagnosis for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than those of IgM in COVID-19.","Int J Infect Dis","Jin, Yujiao","Wang, Miaochan","Zuo, Zhongbao","Fan, Chaoming","Ye, Fei","Cai, Zhaobin","Wang, Ying","Cui, Huaizhong","Pan, Kenu","Xu, Aifang","32251798"],"abstract":["OBJECTIVE: To investigate the diagnostic value of serological testing and dynamic variance of serum antibody in coronavirus disease 2019 (COVID-19). METHODS: This study retrospectively included 43 patients with a laboratory-confirmed infection and 33 patients with a suspected infection, in whom the disease was eventually excluded. The IgM/IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was measured by chemiluminescence immunoassay analysis. RESULTS: Compared to molecular detection, the sensitivities of serum IgM and IgG antibodies to diagnose COVID-19 were 48.1% and 88.9%, and the specificities were 100% and 90.9%, respectively.In the COVID-19 group, the IgM-positive rate increased slightly at first and then decreased over time; in contrast, the IgG-positive rate increased to 100% and was higher than IgM at all times. The IgM-positive rate and titer were not significantly different before and after conversion to virus-negative. The IgG-positive rate was up to 90% and not significantly different before and after conversion to virus-negative. However, the median IgG titer after conversion to virus-negative was double that before, and the difference was significant. CONCLUSIONS: Viral serological testing is an effective means of diagnosis for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than those of IgM in COVID-19."],"journal":"Int J Infect Dis","authors":["Jin, Yujiao","Wang, Miaochan","Zuo, Zhongbao","Fan, Chaoming","Ye, Fei","Cai, Zhaobin","Wang, Ying","Cui, Huaizhong","Pan, Kenu","Xu, Aifang"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251798","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijid.2020.03.065","keywords":["covid-19","diagnosis","immunoglobulin g","immunoglobulin m","sars-cov-2","serological test"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490956414977,"score":413.0295},{"pmid":32387968,"title":"Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","text":["Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19.","J Clin Virol","Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya","32387968"],"abstract":["BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19."],"journal":"J Clin Virol","authors":["Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387968","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104393","keywords":["covid-19","chest ct scan","immunochromatographic assay","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892589588482,"score":399.09137}]}